© 2003 by BMJ Publishing Group & European League Against Rheumatism
REVIEW
Treatment of severe proliferative lupus nephritis: the current state
1 Department of Medicine, Tuen Mun Hospital, Hong Kong, SAR, China
2 Department of Medicine, Queen Mary Hospital, Hong Kong, SAR, China
Correspondence to:
Correspondence to:
Dr C C Mok, Department of Medicine, Tuen Mun Hospital, Tsing Chung Koon Road, New Territories, Hong Kong, China;
ccmok{at}netvigator.com
Despite the development of new modalities, cyclophosphamide (CYC) remains the preferred initial treatment for severe proliferative lupus nephritis. Controversies continue about the best route, dosage, and duration of CYC treatment. For recalcitrant disease, new immunosuppressive and immunomodulating agents, immunoablative high dose CYC, nucleoside analogues, apheresis, and the biological response modifiers can be considered.
Keywords: cytotoxicity; glomerulonephritis; immunosuppressive drugs; toxicities
Abbreviations: AZA, azathioprine; CSA, cyclosporin A; CYC, cyclophosphamide; DPGN, diffuse proliferative glomerulonephritis; IVIg, intravenous immunoglobulin; MMF, mycophenolate mofetil; MP, methylprednisolone; NIH, National Institutes of Health; SLE, systemic lupus erythematosus
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
-
Mak, A., Cheak, A. A. C., Tan, J. Y. S., Su, H. C., Ho, R. C. M., Lau, C. S.
(2009). Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology (Oxford)
48: 944-952
[Abstract] [Full Text] -
Flower, C, Hennis, A, Hambleton, I R, Nicholson, G
(2006). Lupus nephritis in an Afro-Caribbean population: renal indices and clinical outcomes. Lupus
15: 689-694
[Abstract] -
Bihl, G. R., Petri, M., Fine, D. M.
(2006). Kidney biopsy in lupus nephritis: look before you leap. Nephrol Dial Transplant
21: 1749-1752
[Full Text] -
Barber, C E., Geldenhuys, L, Hanly, J G
(2006). Sustained remission of lupus nephritis. Lupus
15: 94-101
[Abstract] -
Ozdemir, F N, Elsurer, R, Akcay, A, Ozdemir, B H, Sezer, S, Kuscu, E, Haberal, M
(2005). Seronegative systemic lupus erythematosus: etiology of nephrotic syndrome and acute renal failure in early postpartum period. Lupus
14: 629-631
[Abstract] -
Fine, D. M.
(2005). Pharmacological Therapy of Lupus Nephritis. JAMA
293: 3053-3060
[Abstract] [Full Text] -
Gorman, C., Bhatia, A., Rahman, A.
(2005). This house believes that low-dose intravenous cyclophosphamide is superior to standard high-dose regimes for treatment of lupus nephritis. Rheumatology (Oxford)
44: 398-401
[Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
